NewsNewsDetails
Analysts are optimistic about leading stocks in the healthcare sector: AbbVie, Agios Pharma, and Resmed receive bullish ratings
Businessinsider
2h ago
Ai Focus
Three analysts have recently expressed bullish views on individual stocks in the healthcare sector. Wells Fargo has maintained a buy rating on AbbVie with a target price of $340; Bank of America Securities has maintained a buy rating on Agios Pharma with a target price of $50; Bank of America Securities has reiterated a buy rating on Resmed with a target price of $320.
Helpful
No.Help

There are several reasons to be optimistic about the healthcare sector. Recently, three analysts have each expressed bullish views on AbbVie (AbbVie, ABBV), Agios Pharma (AGIO), and Resmed (RMD).

AbbVie ( ABBV )

Bank of America analyst Mohit Bansal maintained a 'Buy' rating on AbbVie on October 30th, setting a target price of $340.00. The company's stock closed at $294.89 last Friday.

According to the data from TipRanks.com, Bansal is a five-star analyst with an average return rate of

Currently, analysts have a consistent rating of "strong buy" for AbbVie, with an average target price of $296.55, representing a potential increase of 1.6% from the current level. In a report released on October 30th, TipRanks - DeepSeek also upgraded the stock to "buy" with a target price of $323.00.

Agios Pharma （ AGIO ）

Bank of America securities analyst Alec Stranahan maintained a “buy” rating on Agios Pharma on October 30th, setting a target price of $50.00. The company’s stock closed at $30.55 last Friday, near its 52-week low of $27.14.

According to the data from TipRanks.com, Stranahan is a one-star analyst with an average return rate of

Overall, Wall Street has given Agios Pharma a consistent rating of "Strong Buy" with an average target price of $45.20, which indicates a potential upside of 43.8% from the current level. H.C and Wainwright also began to cover this stock in a report released on October 30th, assigning a "Buy" rating with a target price of $55.00.

Resmed （ RMD ）

Bank of America Securities analyst Lyanne Harrison reiterated today his 'buy' rating on Resmed and set a target price of $320.00. The company's stock closed at $229.94 last Friday.

The average return rate of Harrison is

According to the data from TipRanks.com, Harrison ranks 10,020 out of 12,551 analysts.

Currently, analysts have a consensus rating of "moderate buy" for Resmed, with an average target price of $261.73, representing a potential upside of 6.2% from the current level. In a report released on October 30th, KeyBanc also maintained a "buy" rating for the stock, with a target price of $277.00.

Tip
$0
Like
0
Save
0
Views 45
CoinMeta reminds readers to view blockchain rationally, stay aware of risks, and beware of virtual token issuance and speculation. All content on this site represents market information or related viewpoints only and does not constitute any form of investment advice. If you find sensitive content, please click“Report”，and we will handle it promptly。
Submit
Comment 0
Hot
Latest
No comments yet. Be the first!
Related
Ally Financial Wins Multiple Awards for Best Bank and Best Employer
Ally Financial indicates that the company has recently received multiple recognitions from Money, Fortune, PEOPLE, Forbes, American Banker, and Newsweek, covering aspects such as customer value, workplace culture, leadership, and trust. The company stated that Ally Bank won several first places in the 2027 Best Banks selection by Money, while Fortune, PEOPLE, Forbes, and Newsweek also awarded it rankings in terms of workplace, employer, and trust respectively.
PR Newswire
·2026-11-03 04:44:05
4
In his final public speech before the midterms, Trump focused on the reflecting pool of the Lincoln Memorial
In his last scheduled public speech before the election on Tuesday, U.S. President Donald Trump spent over 20 minutes discussing the renovation of the reflecting pool at the Lincoln Memorial, the restoration of Washington's memorial facilities, and issues related to public safety in the capital, before turning to speak about the mid-term elections, calling them "the most important mid-term elections of our lifetime."
CNBC
·2026-11-03 04:44:02
4
Themes's Leverage Shares plans to launch a 2x long and short ETF before Anthropic IPO: ANUU, ANDD, and ANSS
As Anthropic prepares for its much-anticipated public listing, Themes's Leverage Shares is ready to launch three leveraged and inverse products linked to the company's stock (expected code to be ANT), namely a 2x long ANUU, a 2x short ANDD, and a 1x short ANSS. The company also notes that these products are reset daily, and the returns held over a single day may significantly differ from the cumulative performance of the underlying stock, carrying a relatively high level of risk.
PR Newswire
·2026-11-03 04:44:00
3
After Intel's stock price plummeted by 45% in October, its bet on wafer foundry manufacturing faces a critical test
Due to the deteriorating market prospects of PC, Intel's stock price plummeted by 45% in October, and the company's wafer foundry business is also facing greater pressure. On one hand, Intel benefits from the growth of its data center business; on the other hand, it has to divert some of its advanced 18A production capacity to more mature manufacturing processes due to limited capacity, which puts its efforts to attract external foundry customers to the test.
CNBC
·2026-11-03 04:23:37
16
Tom Lee claims that the sell-off of AI stocks has hit bottom, stating that supply remains tight and the crypto market exhibits resilience
Fundstrat, co-founder, and Bitmine, chairman, stated in an interview with CNBC that the sale of AI stocks has hit bottom, arguing that the AI market is still constrained by supply rather than overcapacity. He also mentioned that the crypto market's relatively limited reaction to the billions of dollars in security incidents at Binance indicates that much of the selling pressure may have already been released. However, chip companies still face financial reporting pressures, and the spot ETF of Bitcoin also shows that funds are continuing to flow out.
Decrypt
·2026-11-03 04:05:35
21
View More
Latest from Author
Refresh
arrow
TSA The new security scanner has a smaller opening, so some luggage may not be able to pass through, but most can still be accommodated.
TSA The new security scanner has a smaller opening, so some luggage may not be able to pass through, but most can still be accommodated.
09-26 23:29   486peopleViews
Micron Technology's stock price fluctuated before its Q4 financial report on September 30; institutions are optimistic about the demand for AI and the increase in storage chip prices.
Micron Technology's stock price fluctuated before its Q4 financial report on September 30; institutions are optimistic about the demand for AI and the increase in storage chip prices.
09-26 21:59   455peopleViews
OpenAI Reveals that AI Proxy Once Accessed Public Data from SEC
OpenAI Reveals that AI Proxy Once Accessed Public Data from SEC
09-26 09:45   478peopleViews
Recommended